These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Isolated Loss of PMS2 Immunohistochemical Expression is Frequently Caused by Heterogenous MLH1 Promoter Hypermethylation in Lynch Syndrome Screening for Endometrial Cancer Patients. Kato A; Sato N; Sugawara T; Takahashi K; Kito M; Makino K; Sato T; Shimizu D; Shirasawa H; Miura H; Sato W; Kumazawa Y; Sato A; Kumagai J; Terada Y Am J Surg Pathol; 2016 Jun; 40(6):770-6. PubMed ID: 26848797 [TBL] [Abstract][Full Text] [Related]
6. [Expression and clinical significance of MMR protein and MLH1 promoter methylation testing in endometrial cancer]. Jin W; Wang LQ; Liu Y; Liu AJ Zhonghua Fu Chan Ke Za Zhi; 2018 Dec; 53(12):823-830. PubMed ID: 30585020 [No Abstract] [Full Text] [Related]
7. Immunohistochemistry for mismatch repair protein deficiency in endometrioid endometrial carcinoma yields equivalent results when performed on endometrial biopsy/curettage or hysterectomy specimens. Chapel DB; Yamada SD; Cowan M; Lastra RR Gynecol Oncol; 2018 Jun; 149(3):570-574. PubMed ID: 29656794 [TBL] [Abstract][Full Text] [Related]
8. Association of tumor morphology with mismatch-repair protein status in older endometrial cancer patients: implications for universal versus selective screening strategies for Lynch syndrome. Rabban JT; Calkins SM; Karnezis AN; Grenert JP; Blanco A; Crawford B; Chen LM Am J Surg Pathol; 2014 Jun; 38(6):793-800. PubMed ID: 24503759 [TBL] [Abstract][Full Text] [Related]
9. Germline MLH1 Mutations Are Frequently Identified in Lynch Syndrome Patients With Colorectal and Endometrial Carcinoma Demonstrating Isolated Loss of PMS2 Immunohistochemical Expression. Dudley B; Brand RE; Thull D; Bahary N; Nikiforova MN; Pai RK Am J Surg Pathol; 2015 Aug; 39(8):1114-20. PubMed ID: 25871621 [TBL] [Abstract][Full Text] [Related]
10. Mismatch Repair Protein Expression in Endometrioid Intraepithelial Neoplasia/Atypical Hyperplasia: Should We Screen for Lynch Syndrome in Precancerous Lesions? Lucas E; Chen H; Molberg K; Castrillon DH; Rivera Colon G; Li L; Hinson S; Thibodeaux J; Lea J; Miller DS; Zheng W Int J Gynecol Pathol; 2019 Nov; 38(6):533-542. PubMed ID: 30383610 [TBL] [Abstract][Full Text] [Related]
11. MLH1/PMS2-deficient Endometrial Carcinomas in a Universally Screened Population: MLH1 Hypermethylation and Germline Mutation Status. Kurpiel B; Thomas MS; Mubeen M; Ring KL; Modesitt SC; Moskaluk CA; Mills AM Int J Gynecol Pathol; 2022 Jan; 41(1):1-11. PubMed ID: 33577226 [TBL] [Abstract][Full Text] [Related]
13. PD-L1 Expression in Mismatch Repair-deficient Endometrial Carcinomas, Including Lynch Syndrome-associated and MLH1 Promoter Hypermethylated Tumors. Sloan EA; Ring KL; Willis BC; Modesitt SC; Mills AM Am J Surg Pathol; 2017 Mar; 41(3):326-333. PubMed ID: 27984238 [TBL] [Abstract][Full Text] [Related]
14. Lynch syndrome screening should be considered for all patients with newly diagnosed endometrial cancer. Mills AM; Liou S; Ford JM; Berek JS; Pai RK; Longacre TA Am J Surg Pathol; 2014 Nov; 38(11):1501-9. PubMed ID: 25229768 [TBL] [Abstract][Full Text] [Related]
15. Endometrial Carcinomas With Subclonal Loss of Mismatch Repair Proteins: A Clinicopathologic and Genomic Study. Mendoza RP; Wang P; Schulte JJ; Tjota MY; Jani I; Martinez AC; Haridas R; Wanjari P; Steinhardt G; Brown N; Betz BL; Chapel DB; Kertowidjojo E; Yamada SD; Bennett JA Am J Surg Pathol; 2023 May; 47(5):589-598. PubMed ID: 36866757 [TBL] [Abstract][Full Text] [Related]
16. Interpretation of Mismatch Repair Protein Immunohistochemistry in Endometrial Carcinoma Should Consider Both Lynch Syndrome Screening and Immunotherapy Susceptibility: An Illustrative Case Report. Chapel DB; Lengyel E; Ritterhouse LL; Lastra RR Int J Gynecol Pathol; 2020 May; 39(3):233-237. PubMed ID: 30807370 [TBL] [Abstract][Full Text] [Related]
17. Lynch Syndrome in Thai Endometrial Cancer Patients. Manchana T; Ariyasriwatana C; Triratanachat S; Phowthongkum P Asian Pac J Cancer Prev; 2021 May; 22(5):1477-1483. PubMed ID: 34048176 [TBL] [Abstract][Full Text] [Related]
18. EPM2AIP1 Immunohistochemistry Can Be Used as Surrogate Testing for MLH1 Promoter Methylation in Endometrial Cancer. Mrkonjic M; Turashvili G Am J Surg Pathol; 2022 Mar; 46(3):376-382. PubMed ID: 34772843 [TBL] [Abstract][Full Text] [Related]
19. Clinicopathologic Comparison of Lynch Syndrome-associated and "Lynch-like" Endometrial Carcinomas Identified on Universal Screening Using Mismatch Repair Protein Immunohistochemistry. Mills AM; Sloan EA; Thomas M; Modesitt SC; Stoler MH; Atkins KA; Moskaluk CA Am J Surg Pathol; 2016 Feb; 40(2):155-65. PubMed ID: 26523542 [TBL] [Abstract][Full Text] [Related]
20. Combined Microsatellite Instability, MLH1 Methylation Analysis, and Immunohistochemistry for Lynch Syndrome Screening in Endometrial Cancers From GOG210: An NRG Oncology and Gynecologic Oncology Group Study. Goodfellow PJ; Billingsley CC; Lankes HA; Ali S; Cohn DE; Broaddus RJ; Ramirez N; Pritchard CC; Hampel H; Chassen AS; Simmons LV; Schmidt AP; Gao F; Brinton LA; Backes F; Landrum LM; Geller MA; DiSilvestro PA; Pearl ML; Lele SB; Powell MA; Zaino RJ; Mutch D J Clin Oncol; 2015 Dec; 33(36):4301-8. PubMed ID: 26552419 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]